Tests budesonide to prevent diarrhea after stem cell transplant in myeloma

Trial details

Who runs it

University of Utah

Trial code

NCT05405387

Record updated

5 June 2026

Original description

A randomized placebo controlled, phase 2 study of budesonide in subjects with multiple myeloma undergoing autologous stem cell transplant (ACST). The study includes a run-in period with 20 patients.Read full original descriptionShow less

A Randomized Phase 2 Trial Investigating the Impact of Budesonide Prophylaxis on Incidence of ≥ Grade 2 Diarrhea in Multiple Myeloma (MM) Patients Undergoing Autologous Stem Cell Transplant

A randomized placebo controlled, phase 2 study of budesonide in subjects with multiple myeloma undergoing autologous stem cell transplant (ACST). The study includes a run-in period with 20 patients.

Inclusion: Subject aged ≥ 18 years; History of histologically confirmed multiple myeloma and/or Plasma Cell Leukemia diagnosis undergoing ASCT who are determined to be fit by the investigator to undergo ASCT with melphalan 200 mg/m2 or melphalan 140 mg/m2 as conditioning; Able to provide informed consent and willing to sign an approved consent form that conforms to federal and institutional guidelines; Adequate organ function as defined as:; --Hepatic:; Total Bilirubin ≤ 2 x institutional upper limit of normal (ULN); AST(SGOT)/ALT(SGPT) ≤ 5 × institutional ULN; For female subjects who have not undergone surgical sterilization: Negative pregnancy test or evidence of post-menopausal status. The post-menopausal status will be defined as having been amenorrheic for 12 months without an alternative medical cause or having undergone surgical sterilization (bilateral oophorectomy or hysterectomy). The following age-specific requirements apply:; Women < 50 years of age:; Amenorrheic for ≥ 12 months following cessation of exogenous hormonal treatments; and; Luteinizing hormone and follicle-stimulating hormone levels in the post-menopausal range for the institution; or; Underwent surgical sterilization (bilateral oophorectomy or hysterectomy); Women ≥ 50 years of age:; Amenorrheic for 12 months or more following cessation of all exogenous hormonal treatments; or; Had radiation-induced menopause with last menses >1 year ago; or; Had chemotherapy-induced menopause with last menses >1 year ago; or; Underwent surgical sterilization (bilateral oophorectomy, bilateral salpingectomy, or hysterectomy); -Patient must have at least 2.5 x 106 CD34 cells in reserve for use if engraftment is delayed.

Exclusion: Receiving other investigational agents, unless deemed acceptable after consultation with the PI; Prior history or current diagnosis of inflammatory bowel disease, microscopic colitis at baseline; Prior history of receiving an allogenic stem cell transplant; Known prior severe hypersensitivity to melphalan or budesonide or any component in their formulations or compounds of similar composition (NCI CTCAE v5.0 Grade ≥ 3); Subjects taking prohibited medications as described in Section 6.6.1. A washout period of prohibited medications for a period of at least five half-lives or 14 days (whichever is shorter) should occur before the start of treatment; Subjects with moderate or severe pre-existing hepatic impairment as classified according to the Child-Pugh system; Medical, psychiatric, cognitive, or other conditions that may compromise the subject's ability to understand the subject information, give informed consent, comply with the study protocol or complete the study; Ongoing or current use of oral budesonide at the time of enrollment.

ClinicalTrials.gov NCT05405387